MedTrace Logo

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

NCT02323191 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 221

Last updated 2020-08-27

No results posted yet for this study

Summary

This Phase 1, open-label, multicenter, global study will evaluate the safety, pharmacokinetics, and activity of emactuzumab and atezolizumab administered in combination in participants with selected locally advanced or metastatic solid tumors that are not amenable to standard treatment.

Participants who receive emactuzumab and atezolizumab will continue to receive study drug as long as they experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data, biopsy results (if available), and clinical status, or withdrawal of consent.

Conditions

  • Solid Cancers

Interventions

DRUG

Atezolizumab

Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.

DRUG

Emactuzumab

Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-19
Primary Completion
2020-08-21
Completion
2020-08-21

Countries

  • United States
  • Belgium
  • France
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02323191 on ClinicalTrials.gov